Application of serine protease inhibitor in preparation of medicine for treating hyperhidrosis
By using serine protease inhibitors to inhibit the activity of sweat gland cells, the problems of high surgical risk and limited drug options in the treatment of hyperhidrosis are solved, and effective hyperhidrosis treatment effects are achieved.
Patent Information
- Application Number
- CN202511076222.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-08-01
- Publication Date
- 2025-09-16
AI Technical Summary
Among the existing treatments for hyperhidrosis, surgical treatment has high risks and uncertain effects, while drug treatment options are limited and the effects are poor.
Serine protease inhibitors are used to inhibit the activity of sweat gland cells, and their effectiveness in treating hyperhidrosis has been verified through animal experiments.
It effectively reduces skin sweating, provides a new drug development solution for the treatment of hyperhidrosis, and improves sweat gland secretion.
Smart Images
Figure CN120643696A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug preparation, in particular to an application of a serine protease inhibitor in the preparation of a drug for treating hyperhidrosis. Background Art
[0002] Hyperhidrosis is a condition characterized by abnormally excessive sweating, characterized by increased local or systemic sweating under normal ambient temperature and conditions, exceeding the physiological range required for thermoregulation. This condition often significantly impacts patients' daily, social, and psychological well-being. Treatment options for hyperhidrosis include surgery and medication. However, surgery carries high risks and may not effectively improve sweating after surgery. Medication is less effective, and the available medications are limited, making it less desirable. Summary of the Invention
[0003] The purpose of the present invention is to address the problems existing in the prior art and to provide an application of a serine protease inhibitor in the preparation of a drug for treating hyperhidrosis.
[0004] To achieve the above-mentioned object, the technical solution adopted by the present invention is as follows: The present invention proves through animal experiments that serine protease inhibitors can inhibit the activity of sweat gland cells. Therefore, this application requests protection for the use of serine protease inhibitors in the preparation of drugs for treating hyperhidrosis.
[0005] The beneficial technical effect of the present invention is: the present invention proves that serine protease inhibitors can inhibit the activity of sweat gland cells, realize the new use of old drugs, improve sweat gland secretion, and provide a new solution for the development of drugs for the treatment of polyangiopathy. BRIEF DESCRIPTION OF THE DRAWINGS
[0006] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0007] Figure 1 This is the sweating test result of Example 1 of the present invention; Figure 2 This is the transmission electron microscopy result of the sweat gland tissue cells in Example 1 of the present invention.
[0008] Figure 3 This is the result of the effect of the serine protease inhibitor in Example 1 of the present invention on calcium ion influx in sweat gland cells. DETAILED DESCRIPTION
[0009] The following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. All other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making any creative efforts shall fall within the scope of protection of the present invention.
[0010] Example 1
[0011] 1. Experimental Materials Experimental animals: C57BL / 6 male mice, 8-10 weeks old, weighing 20-25 g; Grouping: experimental group (drug treatment), control group (normal saline or solvent control), n = 8-10 mice per group; Rearing conditions: SPF environment, 12-h light / dark cycle, free access to food and water; Drugs and reagents: serine protease inhibitor (Camostat Mesilate), physiological saline or solvent (such as DMSO, adjusted according to drug solubility), anesthetic (isoflurane), PBS buffer, 4% paraformaldehyde (for fixation); Instruments and equipment: intraperitoneal syringe (1 mL insulin syringe, 26-30 G needle), electronic balance, dissecting instruments, tissue slicer, fluorescence microscope / confocal microscope, RT-qPCR instrument, Western blot equipment); 2. Experimental Procedure Drug dissolution: Prepare with normal saline or PBS containing 0.1% DMSO according to the properties of the drug, and filter sterilize.
[0012] Injection regimen: Dosage: 10 mg / kg Frequency: Intraperitoneal injection every 48 hours for 2 weeks (7 injections total) Control group: equal volume of normal saline or solvent Sample collection after two weeks: 24 hours after the last injection (to avoid acute drug effects). Representative images taken 5 minutes after pilocarpine injection (sweat test).
[0013] Anesthesia and sacrifice: The animals were sacrificed by cervical dislocation after isoflurane anesthesia.
[0014] 3. Experimental Results 1. Sweat test The skin of the mouse foot pad (the sweat gland-dense area) was photographed 5 minutes after the injection of pilocarpine. Figure 1 showed that sweating in the mouse footpad skin was significantly reduced after treatment with serine protease inhibitors.
[0015] 2. Electron Microscope Photography like Figure 2 Shown are representative transmission electron microscopy images (×12,500) of sweat gland histiocytes. Sweat glands were harvested 5 minutes after pilocarpine injection. The number of sweat granules was counted using ImageJ (n = 6). **P < 0.01 compared to the control group.
[0016] 3. Calcium Influx Experiment To determine the effect of serine protease inhibitors on calcium influx in sweat gland cells, sweat gland cells were extracted from mice and treated with serine protease inhibitors (200 ng / mL) for 48 hours. They were then incubated with the calcium imaging dye Fluo-4 for half an hour. The culture medium was replaced with PBS and the cells were placed under a fluorescence microscope to observe the real-time intracellular calcium fluorescence intensity. One minute later, acetylcholine stimulation was given. Real-time fluorescence showed that the recombinant serine protease inhibitor-treated group was compared with the control group, as shown in Figure 3. Figure 3 As shown in Figure 3, calcium influx was significantly decreased, indicating that serine protease inhibitors can inhibit calcium influx in sweat gland cells.
[0017] Finally, it should be noted that the above embodiments are only used to illustrate rather than limit the technical solutions of the present invention. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that the present invention can still be modified or replaced by equivalents. Any modification or partial replacement that does not depart from the spirit and scope of the present invention should be included in the scope of the claims of the present invention.
Claims
1. Application of serine protease inhibitors in the preparation of drugs for the treatment of hyperhidrosis.
2. The application according to claim 1, characterized in that The medicine is an injection.